오톨루스 테라퓨틱스(AUTL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.91 (-0.52%), 시가총액 $0.43B, 52주 최저~최고 $1.21 ~ $2.68.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple
오톨루스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
오톨루스 테라퓨틱스의 현재 주가는 $1.91 (-0.52%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
오톨루스 테라퓨틱스의 시가총액은 약 $0.43B입니다.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The compa